Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Bolsas y Mercados Espanoles  >  Laboratorios Farmaceuticos Rovi, S.A.    ROVI   ES0157261019

LABORATORIOS FARMACEUTICOS ROVI, S.A.

(ROVI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Bolsas Y Mercados Espanol…
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
37.7(c) 38(c) 39.4(c) 40.5(c) 40.7(c) Last
76 519 58 132 92 399 249 178 93 832 Volume
+2.45% +0.80% +3.68% +2.79% +0.49% Change
More quotes
Financials
Sales 2020 410 M 495 M 495 M
Net income 2020 55,7 M 67,2 M 67,2 M
Net Debt 2020 19,8 M 23,9 M 23,9 M
P/E ratio 2020 40,5x
Yield 2020 0,55%
Sales 2021 478 M 577 M 577 M
Net income 2021 68,6 M 82,8 M 82,8 M
Net cash position 2021 28,4 M 34,3 M 34,3 M
P/E ratio 2021 32,3x
Yield 2021 0,68%
Capitalization 2 255 M 2 718 M 2 721 M
EV / Sales 2020 5,55x
EV / Sales 2021 4,65x
Nbr of Employees 1 310
Free-Float 30,6%
More Financials
Company
Laboratorios Farmaceuticos ROVI SA (ROVI) is a Spain-based company principally engaged in the pharmaceutical industry. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which... 
Sector
Pharmaceuticals
Calendar
03/03Earnings Release
More about the company
Notations Surperformance© of Laboratorios Farmaceuticos Rovi, S.A.
Trading Rating : Investor Rating :
More Ratings
All news about LABORATORIOS FARMACEUTICOS ROVI, S.A.
11/27LABORATORIOS FARMACEUTICOS ROVI S A : The Journal npj Schizophrenia Publishes th..
PU
11/27LABORATORIOS FARMACEUTICOS ROVI S A : The Company publishes the results of the P..
PU
11/24LABORATORIOS FARMACEUTICOS ROVI S A : The Company releases the presentation rela..
PU
11/17LABORATORIOS FARMACEUTICOS ROVI, S.A : Ex-dividend day for final dividend
FA
11/05LABORATORIOS FARMACEUTICOS ROVI S A : ROVI releases the 2020 First Nine Months R..
PU
11/05LABORATORIOS FARMACEUTICOS ROVI S A : The company releases the press release rel..
PU
11/05LABORATORIOS FARMACEUTICOS ROVI S A : First nine months 2020 results press relea..
PU
09/30Lonza confident of 2020 target for Moderna COVID-19 vaccine supply
RE
09/29Lonza confident of 2020 target for Moderna COVID-19 vaccine supply
RE
08/24Moderna, EU conclude advanced talks to supply COVID-19 vaccine candidate
RE
08/24Moderna, EU conclude advanced talks to supply COVID-19 vaccine candidate
RE
07/27LABORATORIOS FARMACEUTICOS ROVI S A : ROVI releases the 2020 First Half Results ..
PU
07/27LABORATORIOS FARMACEUTICOS ROVI S A : The company releases the press release rel..
PU
07/10MODERNA : and ROVI Announce Collaboration for OUS Fill-Finish Manufacturing of M..
AQ
05/13LABORATORIOS FARMACEUTICOS ROVI S A : First quarter 2020 results press release
PU
More news
News in other languages on LABORATORIOS FARMACEUTICOS ROVI, S.A.
2018LABORATORIOS FARMACEUTICOS ROVI SA : publication des résultats annuels
2018LABORATORIOS FARMACEUTICOS ROVI SA : Veröffentlichung des Jahresergebnisses
More news
Stock Trading Strategies
LABORATORIOS FARMACEUTICOS ROVI, S.A. - 08/19
The underlying trend is to the upside
BUY
More Stock Trading Analysis
Chart LABORATORIOS FARMACEUTICOS ROVI, S.A.
Duration : Period :
Laboratorios Farmaceuticos Rovi, S.A. Technical Analysis Chart | ROVI | ES0157261019 | MarketScreener
Technical analysis trends LABORATORIOS FARMACEUTICOS ROVI, S.A.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 33,77 €
Last Close Price 40,70 €
Spread / Highest target 9,34%
Spread / Average Target -17,0%
Spread / Lowest Target -61,9%
EPS Revisions
Managers
NameTitle
Juan López-Belmonte Encina Chief Executive Officer, Executive Director & GM
Juan López-Belmonte López Chairman
Javier López-Belmonte Encina Vice Chairman & Chief Financial Officer
Ibón Gutierro Adúriz Manager-Research & Development
Iván López-Belmonte Encina Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
LABORATORIOS FARMACEUTICOS ROVI, S.A.65.98%2 681
JOHNSON & JOHNSON-0.82%380 876
ROCHE HOLDING AG-4.76%282 467
PFIZER, INC.3.21%212 942
NOVARTIS AG-10.48%206 479
MERCK & CO., INC.-11.61%203 389